[go: up one dir, main page]

MX2016002372A - Beta-caseina a2 y niveles de glucosa en sangre. - Google Patents

Beta-caseina a2 y niveles de glucosa en sangre.

Info

Publication number
MX2016002372A
MX2016002372A MX2016002372A MX2016002372A MX2016002372A MX 2016002372 A MX2016002372 A MX 2016002372A MX 2016002372 A MX2016002372 A MX 2016002372A MX 2016002372 A MX2016002372 A MX 2016002372A MX 2016002372 A MX2016002372 A MX 2016002372A
Authority
MX
Mexico
Prior art keywords
casein
beta
blood glucose
glucose levels
animal
Prior art date
Application number
MX2016002372A
Other languages
English (en)
Other versions
MX376874B (es
Inventor
John Clarke Andrew
Original Assignee
A2 Milk Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52483940&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016002372(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by A2 Milk Co Ltd filed Critical A2 Milk Co Ltd
Publication of MX2016002372A publication Critical patent/MX2016002372A/es
Publication of MX376874B publication Critical patent/MX376874B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/20—Dietetic milk products not covered by groups A23C9/12 - A23C9/18
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
    • A23J1/20—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from milk, e.g. casein; from whey
    • A23J1/202—Casein or caseinates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/142—Amino acids; Derivatives thereof
    • A23K20/147—Polymeric derivatives, e.g. peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/332—Promoters of weight control and weight loss
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/54—Proteins
    • A23V2250/542—Animal Protein
    • A23V2250/5424—Dairy protein
    • A23V2250/54246—Casein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Animal Husbandry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pediatric Medicine (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)

Abstract

Regular el nivel de glucosa en la sangre de un animal que comprende el consumo por el animal de una composición que contiene beta-caseína, o proporcionar la composición al animal para consumo, donde la beta-caseína comprende al menos 75% en peso de beta-caseína A2. Los usos incluyen manejar los síntomas de hiperglicemia y condiciones asociadas que incluyen diabetes. El efecto es tanto agudo (post-exposición a la composición) como continuo.
MX2016002372A 2013-08-23 2014-08-22 Beta-caseina a2 y niveles de glucosa en sangre. MX376874B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361869213P 2013-08-23 2013-08-23
PCT/NZ2014/000172 WO2015026245A1 (en) 2013-08-23 2014-08-22 Beta-casein a2 and blood glucose levels

Publications (2)

Publication Number Publication Date
MX2016002372A true MX2016002372A (es) 2016-12-20
MX376874B MX376874B (es) 2025-03-07

Family

ID=52483940

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016002372A MX376874B (es) 2013-08-23 2014-08-22 Beta-caseina a2 y niveles de glucosa en sangre.
MX2020006720A MX2020006720A (es) 2013-08-23 2016-02-23 Beta-caseina a2 y niveles de glucosa en sangre.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020006720A MX2020006720A (es) 2013-08-23 2016-02-23 Beta-caseina a2 y niveles de glucosa en sangre.

Country Status (17)

Country Link
US (2) US10568933B2 (es)
EP (2) EP3035951B2 (es)
JP (2) JP6866159B2 (es)
KR (2) KR102626825B1 (es)
CN (1) CN105555295A (es)
AU (2) AU2014309522B2 (es)
CA (2) CA2920152A1 (es)
ES (1) ES2899732T5 (es)
IL (2) IL243845B (es)
MX (2) MX376874B (es)
MY (1) MY192873A (es)
NZ (1) NZ717171A (es)
PH (2) PH12019550262A1 (es)
RU (1) RU2698794C2 (es)
SG (2) SG10201801156RA (es)
WO (1) WO2015026245A1 (es)
ZA (1) ZA201600816B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX376874B (es) 2013-08-23 2025-03-07 A2 Milk Co Ltd Beta-caseina a2 y niveles de glucosa en sangre.
CN107708718B (zh) * 2015-04-22 2022-01-11 西达-赛奈医疗中心 用于治疗2型糖尿病的肠内递送的苦味寡肽
CN107708711A (zh) * 2015-05-22 2018-02-16 艾尔牛奶有限公司 β‑酪蛋白A2和抗氧化能力
WO2017003300A1 (en) * 2015-06-29 2017-01-05 The A2 Milk Company Limited A2 beta-casein and viscosity of milk products
WO2017111618A1 (en) * 2015-12-22 2017-06-29 The A2 Milk Company Limited Infant formula comprising human milk peptides
JP2017165661A (ja) * 2016-03-14 2017-09-21 雪印メグミルク株式会社 糖質代謝改善剤
JP7394527B2 (ja) 2016-03-30 2023-12-08 ズィ・エイツー・ミルク・カンパニー・リミテッド ベータカゼイン類および認知機能
US11925197B2 (en) 2016-09-30 2024-03-12 The A2 Milk Company Limited Beta-caseins and gut microbiota
CN113248628B (zh) * 2021-07-13 2021-10-22 南京市妇幼保健院 一种乳源多肽衍生物及其在制备肥胖症防治药物、保健品和食品添加物中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451368B1 (en) 1994-04-11 2002-09-17 New Zealand Dairy Board Method of selecting non-diabetogenic milk or milk products and milk or milk products so selected
DE69634831T2 (de) * 1995-05-16 2006-06-29 A2 Corp. Ltd., Newmarket Nahrungsmittel und herstellungsverfahren
US7094949B2 (en) * 1995-05-16 2006-08-22 A2 Corporation Limited Breeding and milking cows for milk free of β-casein A1
AU771754B2 (en) * 1999-06-29 2004-04-01 New Zealand Milk Institute Limited, The Prophylactic dietary supplement based on milk
AU9037401A (en) 2000-09-08 2002-03-22 New Zealand Dairy Board Milk containing beta-casein with proline at position 67 does not aggravate neurological disorders
US7851147B2 (en) 2002-07-03 2010-12-14 A2 Corporation Limited Method of determining fatty acid composition of milk
US20060280802A1 (en) 2002-10-04 2006-12-14 Campbell Julie H Therapeutic uses of beta-casein a2 and dietary supplement containing beta-casein a2
RU2007105884A (ru) * 2004-07-19 2008-08-27 Н.В. Нютрисиа (Nl) Препарат для применения аспартата и витамина в12 или биотина для регуляции кетоновых тел
EP2745709A1 (en) * 2012-12-24 2014-06-25 Abbott Laboratories, Inc. Nutritional compositions with reduced beta-casein a1 and related methods
MX376874B (es) 2013-08-23 2025-03-07 A2 Milk Co Ltd Beta-caseina a2 y niveles de glucosa en sangre.

Also Published As

Publication number Publication date
NZ717171A (en) 2022-05-27
ZA201600816B (en) 2017-11-29
IL257228A (en) 2018-03-29
IL257228B (en) 2020-02-27
ES2899732T5 (en) 2025-02-05
KR102270059B1 (ko) 2021-06-28
PH12019550262A1 (en) 2023-02-20
PH12016500213A1 (en) 2016-04-25
IL243845A0 (en) 2016-04-21
AU2014309522B2 (en) 2019-11-07
EP3035951B1 (en) 2021-09-15
EP3943100A1 (en) 2022-01-26
ES2899732T3 (es) 2022-03-14
EP3035951A4 (en) 2017-04-19
WO2015026245A1 (en) 2015-02-26
RU2016103489A (ru) 2017-09-28
US20160324922A1 (en) 2016-11-10
JP2016532702A (ja) 2016-10-20
JP7082551B2 (ja) 2022-06-08
US10568933B2 (en) 2020-02-25
IL243845B (en) 2018-02-28
KR20160044580A (ko) 2016-04-25
SG11201600670VA (en) 2016-02-26
AU2014309522A1 (en) 2016-03-10
MX376874B (es) 2025-03-07
MX2020006720A (es) 2020-08-20
RU2698794C2 (ru) 2019-08-30
MY192873A (en) 2022-09-13
EP3035951A1 (en) 2016-06-29
AU2019204101A1 (en) 2019-07-04
JP6866159B2 (ja) 2021-04-28
KR102626825B1 (ko) 2024-01-17
US20200129590A1 (en) 2020-04-30
CA3235298A1 (en) 2015-02-26
KR20210022776A (ko) 2021-03-03
HK1225618A1 (en) 2017-09-15
SG10201801156RA (en) 2018-03-28
JP2019011342A (ja) 2019-01-24
CN105555295A (zh) 2016-05-04
AU2019204101B2 (en) 2021-09-02
PH12016500213B1 (en) 2021-08-04
RU2016103489A3 (es) 2018-06-18
EP3035951B2 (en) 2024-09-04
CA2920152A1 (en) 2015-02-26

Similar Documents

Publication Publication Date Title
MX2016002372A (es) Beta-caseina a2 y niveles de glucosa en sangre.
AR117113A2 (es) Inhibidor de la quinasa que regula la señal de la apoptosis
CO2019002159A2 (es) Análogos de amilina
BR112017009258A2 (pt) sistema eletrônico de fornecimento de vapor e cartomizador para o mesmo
BR112015022776A8 (pt) estruturas de sola e artigos de calçado contendo membros de entressola leves com elementos protetores
MX362375B (es) Extracto de saliva entera de sanguijuela.
MX2019012446A (es) Beta-caseina a2 y reduccion y prevencion de sintomas de intolerancia a la lactosa.
CO6602146A2 (es) Uso combinado de proteínas cryda y cry1fa para el manejo de la resistencia de los insectos
CO6761400A2 (es) Combinación de análogos de glucagón acilados con análogos de insulina
BR112013031707A2 (pt) fraldas descartáveis
AR088347A1 (es) Composicion antimicrobiana y metodo para prolongar la vida util del agua, alimentos o ingredientes de alimentos
BR112015024354A2 (pt) método de determinação do sexo de um embrião em um ovo
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
CO2019012125A2 (es) Inhibidores ip6k
CL2014000490A1 (es) Compuestos derivados de pirazol y sus sales, con actividad inhibidora de sglt1; composicion farmaceutica que los comprende; y su uso para tratar o prevenir diabetes.
MX2015012444A (es) Metodos de diagnostico, seleccion y tratamiento de enfermedades y afecciones provocadas por o asociadas con metanogenos.
CL2012000090A1 (es) Uso de un compuesto derivado de feniltriazol que sirve para el combate de plagas animales tales como insectos y/o tetraníquidos y/o nemátodos, el que es aplicado mediante riego, por goteo, por inmersión o por tratamiento de semillas.
MX368954B (es) Insectos modificados para reducir la expresion genica especifica en los testiculos para los metodos de control biologico.
AR128158A2 (es) Compuesto heterocíclico
CR20140473A (es) Compuestos de pirazol como inhibidores de sglt1
MX2016015092A (es) Inhibidor de proliferacion de celulas madre cancerosas.
ECSP17005294A (es) Composición adhesiva
MX365512B (es) Biomarcador predictivo para terapia contra el cancer.
MX2020004232A (es) Composiciones de cannabinoides y sus metodos de uso.
NI201000173A (es) Uso de dronedarona o una sal aceptable farmacéuticamente de ésta, para la preparación de un medicamento para regular el nivel de potasio en la sangre.

Legal Events

Date Code Title Description
FG Grant or registration